PHARMA MONITOR

Strategic Insights On Pharma Market Trends

By Richa Chaudhary
Month Jun-24
Content
• Therapy Monitor

• Corporate Monitor

• Brand Monitor
Therapy Monitor
Evolution Index (EI)
In the pharmaceutical industry, the Evolution Index is a crucial tool for strategic decision-making.
It measures a product's growth relative to its market, offering valuable insights for maximizing
profitability and navigating market competition effectively. With a range from-100 to positive
values, this index enables companies to make informed, flexible decisions and stay ahead in a
competitive landscape.

Analyzing the evolution index over time in combination with the current sales gives us clear
picture how the company products are competing on the market against the total market sales.

100 + (Brand Growth%) x 100)

Evolution Index =
100 + (Market Growth%) x 100)
Therapy Monitor MTH Jun 24
SUPER GROUP
VAL % Gr % Contri EI Incr Gain
o With the onset of Monsoon across the
subcontinent there was a rise seen in sales of drugs IPM 17502.4 8.8% 1422.5
related to Respiratory, Anit-Infective, Anti-Maleria CARDIAC 2375.5 9.7% 13.57% 101% 209.6
and Gastrointestinal SG in MTH June 24 GASTRO INTESTINAL 2176.0 10.7% 12.43% 102% 209.7
ANTI-INFECTIVES 2112.3 17.2% 12.07% 108% 310.7
o Increased number of Pollen allergies cases reported ANTI DIABETIC 1611.1 5.8% 9.20% 97% 88.4
VITAMINS / MINERALS / NUTRIENTS 1515.2 2.6% 8.66% 94% 38.4
in Jun 24 lead to demand for Anti Allergic
RESPIRATORY 1253.9 19.2% 7.16% 110% 202.3
medication along with Anti Histamine, Nasal PAIN / ANALGESICS 1210.7 5.7% 6.92% 97% 65.1
Decongestants and Anti Tussive preparations. DERMA 1195.2 9.0% 6.83% 100% 98.3
NEURO / CNS 1103.7 8.4% 6.31% 100% 85.6
o Drugs used in treatment of viral infections, fevers, GYNAECOLOGICAL 563.0 0.1% 3.22% 92% 0.4
and vector-borne diseases along with drugs used BLOOD RELATED 533.4 6.5% 3.05% 98% 32.3
for treating general weakness and body ache also ANTI-NEOPLASTICS 401.2 7.1% 2.29% 98% 26.6
performed well in Jun 24 OPHTHAL / OTOLOGICALS 307.2 1.7% 1.76% 93% 5.0
HORMONES 294.5 7.3% 1.68% 99% 20.2
UROLOGY 294.2 9.8% 1.68% 101% 26.3
o There was a significant rise seen in the sales of
VACCINES 154.3 0.7% 0.88% 93% 1.1
Anti-Tuberculosis drugs possibly due to stocking up OTHERS 133.1 4.8% 0.76% 96% 6.0
at patient level fearing the supply chain issues of STOMATOLOGICALS 113.1 -1.6% 0.65% 90% -1.8
previous months to prevail further SEX STIMULANTS / REJUVENATORS 110.8 -6.0% 0.63% 86% -7.1
ANTI MALARIALS 44.0 13.4% 0.25% 104% 5.2
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
Corporate Monitor
MTH Jun 24

#1 - 20 Rank
SUPER GROUP
VAL % Gr % MS G/L %MS EI Incr Gain

o IPM exhibited a growth of 8.8%. Corporates IPM 17502.4 8.8% 100% 100% 1422.5
like Sun, Mankind, Cipla, Torrent, Intas, 1 SUN* 1513.2 10.6% 8.6% 102% 145.0
Alkem, Macleods, Aristo, GSK, USV, 2 ABBOTT* 1131.1 6.5% 6.5% 98% 68.6
3 MANKIND 934.6 12.0% 5.3% 103% 100.2
Glenmark & Micro outperformed the 4 CIPLA 917.7 16.5% 5.2% 107% 129.7
market with a robust double-digit growth in 5 TORRENT 704.1 13.6% 4.0% 104% 84.4
Jun 24 6 INTAS 667.9 15.8% 3.8% 106% 91.4
7 ALKEM* 629.2 15.3% 3.6% 106% 83.7
8 ZYDUS* 626.5 1.2% 3.6% 93% 7.5
9 LUPIN 614.0 9.7% 3.5% 101% 54.2
o Sun, Mankind and Cipla recorded 100+ Cr 10 DR. REDDYS 559.8 7.8% 3.2% 99% 40.6
incr gain over LYSM 11 MACLEODS 556.4 10.8% 3.2% 102% 54.0
12 ARISTO 528.6 17.7% 3.0% 108% 79.5
13 EMCURE* 513.1 4.3% 2.9% 96% 21.4
o Cipla (+0.30%), Intas and Aristo (+0.23%) 14 GSK 432.8 12.6% 2.5% 103% 48.4
15 USV 381.3 13.9% 2.2% 105% 46.5
and Alkem (+0.20%) saw highest % MS gain 16 GLENMARK 374.8 16.4% 2.1% 107% 52.9
over LYSM 17 IPCA 316.9 8.9% 1.8% 100% 25.9
18 MICRO 295.9 15.6% 1.7% 106% 40.0
19 ERIS LS 278.7 9.3% 1.6% 100% 23.6
20 PFIZER* 278.6 5.7% 1.6% 97% 15.1
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH Jun 24

#21 - 40 Rank
SUPER GROUP
VAL % Gr % MS G/L %MS EI Incr Gain

o Fourrts continued with highest growth IPM 17502.4 8.8% 100% 100% 1422.5
21 ALEMBIC 184.8 8.5% 1.1% 100% 14.4
among 21 to 40 rank corporates in the IPM 22 SANOFI INDIA 172.1 -1.4% 1.0% 91% -2.4
for the month of Jun as well. Other 23 FDC 168.7 22.2% 1.0% 112% 30.7
corporates like FDC, La Renon, Himalaya, 24 LA RENON 140.2 13.1% 0.8% 104% 16.2
Indoco, Corona, Hetero, Bharat Serums, 25 HIMALAYA 134.3 16.6% 0.8% 107% 19.1
Blue Cross and Wallace registered a 26 AJANTA 127.8 7.6% 0.7% 99% 9.1
27 JB CHEMICALS 124.6 9.1% 0.7% 100% 10.4
double-digit growth.
28 CADILA 119.6 1.5% 0.7% 93% 1.8
o Sanofi was the only corp to register a 29 INDOCO 111.9 10.1% 0.6% 101% 10.3
30 CORONA 111.2 14.9% 0.6% 106% 14.4
degrowth among the top 40 corps in IPM 31 HETERO 102.5 10.1% 0.6% 101% 9.4
due to its recent partnership with Cipla and 32 BHARAT SERUMS 101.4 11.7% 0.6% 103% 10.6
Emcure for distribution and marketing of its 33 FOURRTS 96.0 28.1% 0.5% 118% 21.1
CSN & Cadio basket respectively 34 FRANCO 95.8 7.2% 0.5% 99% 6.5
35 MEDLEY 93.4 5.9% 0.5% 97% 5.2
o Most corporates held on to MS for Jun 24 36 BLUE CROSS 89.5 11.9% 0.5% 103% 9.5
37 HEGDE & HEGDE 87.3 1.0% 0.5% 93% 0.9
38 WALLACE* 83.9 10.1% 0.5% 101% 7.7
39 SYSTOPIC 80.7 4.6% 0.5% 96% 3.6
40 APEX 78.0 6.9% 0.4% 98% 5.0
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH Jun 24

#41 - 60 Rank
SUPER GROUP
VAL % Gr % MS G/L %MS EI Incr Gain

IPM 17502.4 8.8% 100% 100% 1422.5

o Troikaa, Akumentis & Wockhardt exhibited 41 NATCO 76.2 4.6% 0.4% 96% 3.3
double digit growth over LYSM 42 MEYER 74.3 5.8% 0.4% 97% 4.1
43 ASTRAZENECA 74.1 2.5% 0.4% 94% 1.8
44 WIN-MEDICARE 72.4 6.3% 0.4% 98% 4.3
45 Nutricia International [Link] 62.2 3.5% 0.4% 95% 2.1
o Apex, Meyer, Novartis, BI, Danone, Piramal, 46 BOEHRINGER INGELHEIM 61.9 1.2% 0.4% 93% 0.7
Janssen, Raptakos and Akumentis saw a 47 FRESENIUS 58.6 -3.9% 0.3% 88% -2.4
degrowth over MTH Apr 23 48 PROCTER AND GAMBLE HEALTH 58.4 -7.2% 0.3% 85% -4.6
49 BAYER ZYDUS 57.6 -3.2% 0.3% 89% -1.9
50 TROIKAA 56.2 11.9% 0.3% 103% 6.0
51 MSD* 56.2 3.7% 0.3% 95% 2.0
o Troikaa capitalized on the seasonality with 52 JOHNSON & JOHNSON 55.7 -16.4% 0.3% 77% -10.9
its brands like Dynapar and Tess, while 53 PHARMED 53.4 0.5% 0.3% 92% 0.3
Akumentis performance was fueled by its 54 ALLERGAN 52.0 5.6% 0.3% 97% 2.8
non seasonality products like Rosycap, 55 PIRAMAL 51.1 -15.8% 0.3% 77% -9.6
Benitowa, Lineator 56 MERCK 48.4 3.1% 0.3% 95% 1.5
57 AKUMENTIS 47.3 12.1% 0.3% 103% 5.1
58 RAPTAKOS 47.2 -4.1% 0.3% 88% -2.0
59 WOCKHARDT 46.6 10.2% 0.3% 101% 4.3
60 RPG 42.9 8.8% 0.2% 100% 3.5
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH Jun 24

#61 - 80 Rank
SUPER GROUP
VAL % Gr % MS G/L %MS EI Incr Gain

IPM 17502.4 8.8% 100% 100% 1422.5

o Among the 60th to 80th rank corporates 61 SAMARTH 39.9 6.7% 0.2% 98% 2.5
62 CENTAUR 39.5 47.8% 0.2% 136% 12.8
Centaur, Mylan, KLM, Aurobindo Pharma,
63 MYLAN 38.6 31.0% 0.2% 120% 9.1
Linux Labs, Serdia (Servier India) & MSN 64 NOVARTIS* 38.0 -14.7% 0.2% 78% -6.5
registered a double-digit growth over LYSM 65 MANEESH* 36.9 -0.2% 0.2% 92% -0.1
66 KLM 36.7 22.2% 0.2% 112% 6.7
67 INTEGRACE HEALTH 36.4 3.4% 0.2% 95% 1.2
68 ALBERT DAVID 35.6 6.2% 0.2% 98% 2.1
o Centaur performance was driven by brands
69 EAST INDIA 35.0 5.7% 0.2% 97% 1.9
like Sinarest & Kofarest. 70 TABLETS INDIA 34.5 2.6% 0.2% 94% 0.9
71 Aurobindo Pharmaceuticals Ltd. 34.3 37.3% 0.2% 126% 9.3
72 BIOLOGICAL E 34.0 5.3% 0.2% 97% 1.7
o Mylan’s Anti-Hypotensive brand Inramed 73 SERUM INSTITUTE 33.0 -1.0% 0.2% 91% -0.3
74 LINUX LAB. 32.2 35.6% 0.2% 125% 8.4
continues to drive the performance for the
75 SERDIA 32.1 10.3% 0.2% 101% 3.0
corporates. 76 WALTER BUSHNELL 31.0 4.0% 0.2% 96% 1.2
77 UNIMED TL 30.2 5.3% 0.2% 97% 1.5
78 LEEFORD HC 29.2 2.5% 0.2% 94% 0.7
79 MSN 28.1 19.7% 0.2% 110% 4.6
80 NEON 27.4 1.9% 0.2% 94% 0.5
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Corporate Monitor
MTH Jun 24

#81 - 100 Rank

SUPER GROUP
VAL % Gr % MS G/L %MS EI Incr Gain

IPM 17502.4 8.8% 100% 100% 1422.5

81 GENO 25.3 6.0% 0.1% 97% 1.4
82 OVERSEAS 25.1 21.3% 0.1% 111% 4.4
83 GUFIC BIOSCIENCE 23.7 36.8% 0.1% 126% 6.4
o Overseas, Gufic Biosciences, UNS, Lloyd 84 MODI MUNDI 23.7 3.8% 0.1% 95% 0.9
85 MED MANOR 22.5 2.5% 0.1% 94% 0.6
HC & Celon Labs out performed the market
86 OZONE 22.4 9.6% 0.1% 101% 2.0
with double digit growth 87 AIMIL 21.8 -5.4% 0.1% 87% -1.2
88 UNS 21.4 16.5% 0.1% 107% 3.0
89 SHREYA 21.3 4.0% 0.1% 96% 0.8
o In this slab all corporates were able to hold 90 KEPLER HC 21.0 6.5% 0.1% 98% 1.3
91 UNISON 20.2 5.2% 0.1% 97% 1.0
on MS, despite the degrowth registered by
92 LLOYD HC 19.9 10.2% 0.1% 101% 1.8
a few. 93 GALDERMA 18.9 6.0% 0.1% 97% 1.1
94 CELON LABS 18.6 73.8% 0.1% 160% 7.9
95 CHARAK 16.7 -21.6% 0.1% 72% -4.6
96 ALNICHE LIFE SCIENCE 16.3 -16.3% 0.1% 77% -3.2
97 LINCOLN 16.0 -9.9% 0.1% 83% -1.8
98 JAGSONPAL 15.7 -13.4% 0.1% 80% -2.4
99 ICPA 15.0 -17.6% 0.1% 76% -3.2
100 FUSION HEALTHCARE 14.5 -8.2% 0.1% 84% -1.3
<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Brand Monitor
 Brand Monitor #1 – 20
MTH Jun 24
% MS in G/L % MS EI against
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR Incr Gain
IPM in IPM supergroup
17502.4 8.8% 100% 1422.5
1 GSK GLAXOSMITHKLINE PHARMACEUTICALS AUGMENTIN ANTI-INFECTIVES 17% 75.7 41.0% 0.4% 120% 22.0
2 USV USV PVT LTD GLYCOMET GP ANTI DIABETIC 6% 66.4 2.3% 0.4% 97% 1.5
3 HIMALAYA HIMALAYA DRUG COMPANY LIV.52 GASTRO INTESTINAL 11% 58.7 32.0% 0.3% 119% 14.2
4 SUN* RANBAXY LABORATORIES LTD ROSUVAS CARDIAC 10% 52.8 22.2% 0.3% 111% 9.6
5 CIPLA CIPLA LTD. FORACORT RESPIRATORY 19% 51.1 5.0% 0.3% 88% 2.4
6 ABBOTT* ABBOTT INDIA LTD. UDILIV GASTRO INTESTINAL 11% 49.8 19.2% 0.3% 108% 8.0
7 MANKIND MANKIND PHARMACEUTICALS LTD. MANFORCE SEX STIMULANTS / REJUVENATORS -6% 48.8 -18.3% 0.3% 87% -10.9
8 ALKEM* ALKEM LABORATORIES LTD. PAN GASTRO INTESTINAL 11% 47.8 15.3% 0.3% 104% 6.3
9 FDC FDC LTD. ELECTRAL GASTRO INTESTINAL 11% 46.4 41.2% 0.3% 128% 13.5
10 ABBOTT* ABBOTT INDIA LTD. THYRONORM HORMONES 7% 45.7 10.3% 0.3% 103% 4.3
11 ARISTO ARISTO PHARMACEUTICALS [Link] MONOCEF ANTI-INFECTIVES 17% 45.1 42.5% 0.3% 122% 13.5
12 EMCURE* EMCURE PHARMACEUTICALS LTD OROFER-XT BLOOD RELATED 6% 44.9 42.3% 0.3% 134% 13.3
13 ABBOTT* NOVO NORDISK INDIA PVT LTD MIXTARD ANTI DIABETIC 6% 44.5 -10.5% 0.3% 85% -5.2
14 ALKEM* ALKEM LABORATORIES LTD. PAN D GASTRO INTESTINAL 11% 40.9 29.5% 0.2% 117% 9.3
15 WIN-MEDICARE WIN-MEDICARE PVT. LTD. BETADINE DERMA 9% 40.8 4.0% 0.2% 95% 1.6
16 ABBOTT* NOVO NORDISK INDIA PVT LTD RYZODEG ANTI DIABETIC 6% 40.3 8.6% 0.2% 103% 3.2
17 IPCA IPCA LABORATORIES PVT LTD. ZERODOL SP PAIN / ANALGESICS 6% 39.6 6.7% 0.2% 101% 2.5
18 CIPLA CIPLA LTD. BUDECORT RESPIRATORY 19% 38.1 42.0% 0.2% 119% 11.3
19 ARISTO ARISTO PHARMACEUTICALS [Link] PANTOP GASTRO INTESTINAL 11% 37.7 17.9% 0.2% 107% 5.7
20 USV USV PVT LTD ECOSPRIN AV CARDIAC 10% 35.8 16.7% 0.2% 106% 5.1

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
 Brand Monitor #21 – 40
MTH Jun 24
% MS in G/L % MS EI against
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR Incr Gain
IPM in IPM supergroup
17502.4 8.8% 100% 1422.5
21 ABBOTT* NOVO NORDISK INDIA PVT LTD RYBELSUS ANTI DIABETIC 6% 35.5 28.2% 0.2% 121% 7.8
22 GSK GLAXOSMITHKLINE PHARMACEUTICALS CALPOL PAIN / ANALGESICS 6% 35.4 16.3% 0.2% 110% 5.0
23 CIPLA CIPLA LTD. DUOLIN RESPIRATORY 19% 34.7 26.5% 0.2% 106% 7.3
24 ALKEM* ALKEM LABORATORIES LTD. CLAVAM ANTI-INFECTIVES 17% 34.5 17.1% 0.2% 100% 5.0
25 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA CARDIAC 10% 34.0 10.0% 0.2% 100% 3.1
26 SANOFI INDIA SANOFI INDIA LTD. LANTUS ANTI DIABETIC 6% 33.0 -4.5% 0.2% 90% -1.5
27 SUN* SUN PHARMA LABORATORIES LTD. LEVIPIL NEURO / CNS 8% 32.9 11.2% 0.2% 103% 3.3
28 CADILA CADILA PHARMACEUTICALS LTD ACILOC GASTRO INTESTINAL 11% 32.4 7.7% 0.2% 97% 2.3
29 ASTRAZENECA ASTRAZENECA PHARMA INDIA LTD BRILINTA CARDIAC 10% 32.1 34.2% 0.2% 122% 8.2
30 ARISTO ARISTO PHARMACEUTICALS [Link] MIKACIN ANTI-INFECTIVES 17% 31.8 23.1% 0.2% 105% 6.0
31 MSD* MSD PHARMACEUTICALS PRIVATE LTD. JANUMET ANTI DIABETIC 6% 31.7 8.0% 0.2% 102% 2.3
32 APEX APEX LABORATORIES LTD. ZINCOVIT VITAMINS / MINERALS / NUTRIENTS 3% 31.4 2.8% 0.2% 100% 0.9
33 ABBOTT* NOVO NORDISK INDIA PVT LTD TRESIBA ANTI DIABETIC 6% 30.5 38.9% 0.2% 131% 8.5
34 FRANCO FRANCO INDIAN PHARMACEUTICALS DEXORANGE BLOOD RELATED 6% 28.7 -1.0% 0.2% 93% -0.3
35 TORRENT TORRENT PHARMACEUTICALS LTD. CHYMORAL FORTE PAIN / ANALGESICS 6% 28.6 21.4% 0.2% 115% 5.1
36 JOHNSON & JOHNSON
JOHNSON & JOHNSON ULTRACET PAIN / ANALGESICS 6% 28.6 -17.2% 0.2% 78% -5.9
37 PFIZER* PFIZER LTD BECOSULES VITAMINS / MINERALS / NUTRIENTS 3% 28.5 0.9% 0.2% 98% 0.3
38 TORRENT TORRENT PHARMACEUTICALS LTD. SHELCAL VITAMINS / MINERALS / NUTRIENTS 3% 27.9 2.8% 0.2% 100% 0.8
39 GSK GLAXOSMITHKLINE PHARMACEUTICALS T BACT DERMA 9% 27.7 -1.2% 0.2% 91% -0.3
40 SUN* RANBAXY LABORATORIES LTD VOLINI PAIN / ANALGESICS 6% 27.4 -22.3% 0.2% 74% -7.8

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
 Brand Monitor #41 – 60
MTH Jun 24
% MS in G/L % MS EI against
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR Incr Gain
IPM in IPM supergroup
17502.4 8.8% 100% 1422.5
41 GSK GLAXOSMITHKLINE PHARMACEUTICALS BETNOVATE N DERMA 9% 27.2 9.4% 0.2% 100% 2.3
42 Nutricia InternationalNUTRICIA
[Link] INTERNATIONAL [Link] DEXOLAC 1 VITAMINS / MINERALS / NUTRIENTS 3% 27.1 24.5% 0.2% 121% 5.3
43 MANKIND MANKIND PHARMACEUTICALS LTD. PREGA NEWS OTHERS 5% 26.3 -12.1% 0.2% 84% -3.6
44 ABBOTT* ABBOTT INDIA LTD. VERTIN NEURO / CNS 8% 26.3 9.4% 0.2% 101% 2.3
45 ABBOTT* ABBOTT INDIA LTD. DUPHALAC GASTRO INTESTINAL 11% 26.1 10.1% 0.1% 99% 2.4
46 LUPIN LUPIN LTD GLUCONORM-G ANTI DIABETIC 6% 25.9 0.9% 0.1% 95% 0.2
47 MANKIND MANKIND PHARMACEUTICALS LTD. MOXIKIND CV ANTI-INFECTIVES 17% 25.6 25.8% 0.1% 107% 5.3
48 ABBOTT* NOVO NORDISK INDIA PVT LTD NOVOMIX ANTI DIABETIC 6% 25.3 -6.0% 0.1% 89% -1.6
49 GSK GLAXOSMITHKLINE PHARMACEUTICALS BETNOVATE C DERMA 9% 25.3 17.7% 0.1% 108% 3.8
50 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA H CARDIAC 10% 24.9 23.8% 0.1% 113% 4.8
51 PFIZER* PFIZER LTD MINIPRESS XL CARDIAC 10% 24.8 22.1% 0.1% 111% 4.5
52 MICRO MICRO LABS LTD DOLO PAIN / ANALGESICS 6% 24.7 16.8% 0.1% 111% 3.6
53 INTAS INTAS PHARMACEUTICALS LTD GABAPIN NT NEURO / CNS 8% 24.7 34.3% 0.1% 124% 6.3
54 SUN* SUN PHARMA LABORATORIES LTD. GEMER ANTI DIABETIC 6% 24.5 -6.7% 0.1% 88% -1.8
55 SUN* RANBAXY LABORATORIES LTD MOXCLAV ANTI-INFECTIVES 17% 24.0 43.8% 0.1% 123% 7.3
56 INTAS INTAS PHARMACEUTICALS LTD LEVERA NEURO / CNS 8% 23.9 8.8% 0.1% 100% 1.9
57 ALKEM* ALKEM LABORATORIES LTD. A TO Z NS VITAMINS / MINERALS / NUTRIENTS 3% 23.7 16.8% 0.1% 114% 3.4
58 SUN* SUN PHARMA LABORATORIES LTD. SUSTEN GYNAECOLOGICAL 0% 23.4 2.8% 0.1% 103% 0.6
59 USV USV PVT LTD ECOSPRIN GOLD CARDIAC 10% 23.4 33.0% 0.1% 121% 5.8
60 GLENMARK GLENMARK PHARMACEUTICALS LTD. CANDID DERMA 9% 23.0 40.0% 0.1% 128% 6.6

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
 Brand Monitor #61 – 80
MTH Jun 24
% MS in G/L % MS EI against
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR Incr Gain
IPM in IPM supergroup
17502.4 8.8% 100% 1422.5
61 GLENMARK GLENMARK PHARMACEUTICALS LTD. TELMA AM CARDIAC 10% 22.9 11.4% 0.1% 102% 2.3
62 ABBOTT* ABBOTT HEALTHCARE PVT. LTD STEMETIL GASTRO INTESTINAL 11% 22.6 17.0% 0.1% 106% 3.3
63 INTAS INTAS PHARMACEUTICALS LTD ZORYL-M ANTI DIABETIC 6% 22.4 7.9% 0.1% 102% 1.6
64 CIPLA CIPLA LTD. ASTHALIN RESPIRATORY 19% 22.2 13.7% 0.1% 95% 2.7
65 SUN* SUN PHARMA LABORATORIES LTD. MONTEK-LC RESPIRATORY 19% 22.2 49.5% 0.1% 125% 7.3
66 SUN* SUN PHARMA LABORATORIES LTD. PANTOCID GASTRO INTESTINAL 11% 22.1 10.9% 0.1% 100% 2.2
67 PFIZER* PFIZER LTD COREX DX RESPIRATORY 19% 22.1 81.3% 0.1% 152% 9.9
68 ABBOTT* ABBOTT INDIA LTD. DUPHASTON GYNAECOLOGICAL 0% 21.9 3.5% 0.1% 103% 0.7
69 ALKEM* ALKEM LABORATORIES LTD. TAXIM O ANTI-INFECTIVES 17% 21.6 15.1% 0.1% 98% 2.8
70 MANKIND MANKIND PHARMACEUTICALS LTD. UNWANTED KIT GYNAECOLOGICAL 0% 21.6 -0.2% 0.1% 100% 0.0
71 DR. REDDYS DR. REDDYS LABORATORIES LTD ECONORM GASTRO INTESTINAL 11% 21.3 12.5% 0.1% 102% 2.4
72 JB CHEMICALS JB CHEMICALS CILACAR CARDIAC 10% 21.2 -2.2% 0.1% 89% -0.5
73 FDC FDC LTD. ZIFI ANTI-INFECTIVES 17% 21.2 3.8% 0.1% 89% 0.8
74 GSK GLAXOSMITHKLINE PHARMACEUTICALS ELTROXIN HORMONES 7% 21.1 -8.6% 0.1% 85% -2.0
75 ALKEM* ALKEM LABORATORIES LTD. XONE ANTI-INFECTIVES 17% 20.7 34.5% 0.1% 115% 5.3
76 ZYDUS* ZYDUS CADILA - ZHL LIPAGLYN CARDIAC 10% 20.6 -14.1% 0.1% 78% -3.4
77 CIPLA CIPLA LTD. MONTAIR LC RESPIRATORY 19% 20.6 32.0% 0.1% 111% 5.0
78 TORRENT TORRENT PHARMACEUTICALS LTD. TEDIBAR DERMA 9% 20.4 86.8% 0.1% 171% 9.5
79 ALEMBIC ALEMBIC LTD AZITHRAL ANTI-INFECTIVES 17% 20.4 16.6% 0.1% 99% 2.9
80 CIPLA CIPLA LTD. DYTOR CARDIAC 10% 20.4 6.7% 0.1% 97% 1.3

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
 Brand Monitor #81 – 100
MTH Jun 24
% MS in G/L % MS EI against
RANK CORPORATE COMPANY BRAND SG SG GR% VAL % GR Incr Gain
IPM in IPM supergroup
17502.4 8.8% 100% 1422.5
81 ARISTO ARISTO PHARMACEUTICALS [Link] MERO ANTI-INFECTIVES 17% 20.3 37.2% 0.1% 117% 5.5
82 MANKIND MANKIND PHARMACEUTICALS LTD. AMLOKIND-AT CARDIAC 10% 20.1 11.2% 0.1% 101% 2.0
83 GSK GLAXOSMITHKLINE PHARMACEUTICALS CEFTUM ANTI-INFECTIVES 17% 20.0 62.9% 0.1% 139% 7.7
84 ARISTO ARISTO PHARMACEUTICALS [Link] MONOCEF SB ANTI-INFECTIVES 17% 20.0 22.8% 0.1% 105% 3.7
85 ABBOTT* ABBOTT INDIA LTD. CREMAFFIN PLUS GASTRO INTESTINAL 11% 19.9 17.8% 0.1% 106% 3.0
86 ARISTO ARISTO PHARMACEUTICALS [Link] MONTAZ ANTI-INFECTIVES 17% 19.7 18.5% 0.1% 101% 3.1
87 TORRENT TORRENT PHARMACEUTICALS LTD. NEXPRO RD GASTRO INTESTINAL 11% 19.6 17.9% 0.1% 107% 3.0
88 MANKIND MANKIND PHARMACEUTICALS LTD. DYDROBOON GYNAECOLOGICAL 0% 19.5 1.4% 0.1% 101% 0.3
89 CIPLA CIPLA LTD. SEROFLO RESPIRATORY 19% 19.2 18.8% 0.1% 100% 3.0
90 MACLEODS MACLEODS PHARMACEUTICALS [Link] MEROMAC ANTI-INFECTIVES 17% 19.2 28.0% 0.1% 109% 4.2
91 USV USV PVT LTD GLYCOMET TRIO ANTI DIABETIC 6% 19.1 1.0% 0.1% 95% 0.2
92 JB CHEMICALS JB CHEMICALS RANTAC GASTRO INTESTINAL 11% 19.0 14.9% 0.1% 104% 2.5
93 TORRENT TORRENT PHARMACEUTICALS LTD. NIKORAN CARDIAC 10% 19.0 14.1% 0.1% 104% 2.3
94 SANOFI INDIA SANOFI INDIA LTD. ALLEGRA RESPIRATORY 19% 19.0 9.8% 0.1% 92% 1.7
95 TORRENT TORRENT PHARMACEUTICALS LTD. SHELCAL XT VITAMINS / MINERALS / NUTRIENTS 3% 18.9 1.2% 0.1% 99% 0.2
96 BOEHRINGER INGELHEIM
BOEHRINGER INGELHEIM JARDIANCE ANTI DIABETIC 6% 18.8 -7.9% 0.1% 87% -1.6
97 SUN* SUN PHARMA LABORATORIES LTD. SOMPRAZ D GASTRO INTESTINAL 11% 18.7 15.9% 0.1% 105% 2.6
98 BLUE CROSS BLUE CROSS LABORATORIES LTD MEFTAL SPAS GASTRO INTESTINAL 11% 18.2 -5.7% 0.1% 85% -1.1
99 GSK GLAXOSMITHKLINE PHARMACEUTICALS BETNESOL HORMONES 7% 17.7 62.0% 0.1% 151% 6.8
100 ARISTO ARISTO PHARMACEUTICALS [Link] MONOCEF O ANTI-INFECTIVES 17% 17.7 37.3% 0.1% 117% 4.8

<= 94% 95- 105% >= 106%

EI – Evolution Index, TA – Therapy areas, SG – Super Group, LYSM – Last Year Same Month, Incr gain – Incremental Val over last year same month
Stars of the month

Incremental Gain % MS Gain Highest EI

• Augmentin
• Augmentin • Orofer XT
• Liv 52 • Liv 52 • Corex DX
• Electral • Electral • Tedibar
• Monocef
• Monocef • Ceftum
• Orofer XT • Orofer XT • Betnesol
• Budecort
 Thank you

Richa Chaudhary
richac@[Link]
+91-9769797951

Visit us at: [Link]